ILDNCT07344987
Effect of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease
A study testing Air Purifier (with Filter) Arm and Purifier (without Filter) Arm in people with ILD, run by Peking Union Medical College.
Trial summary
Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute… Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- ILD
- What is being tested?
- Air Purifier (with Filter) Arm and Purifier (without Filter) Arm
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Mar 2026to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients diagnosed with interstitial lung disease (ILD).
- Stable disease status, defined as no hospitalization due to acute exacerbation within the past month.
Who cannot join
- Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders.
- A history of respiratory tract infection within the past two weeks.
About this study
Official title: A Randomized Crossover Trial of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease
Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.
- Conditions
- ILD
- Being tested
- Air Purifier (with Filter) Arm, Purifier (without Filter) Arm
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Air Purifier (with Filter) ArmBehavioural
Place an air purifier with high-efficiency filters in the home, and turn it on for at least 18 hours every day.
Purifier (without Filter) ArmBehavioural
Place an air purifier without a filter in the home.
| Study group | Role | What they receive |
|---|---|---|
| Purifier (without Filter) Arm | Sham comparator | Not described Receives: Behavioral: Purifier (without Filter) Arm |
| Air Purifier (with Filter) Arm | Experimental | Not described Receives: Behavioral: Air Purifier (with Filter) Arm |
What is being measured
The primary outcome is the main question the study is designed to answer.
Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score)
St. George's Respiratory Questionnaire (SGRQ):Score Range:Minimum score: 0 points;Maximum score: 100 points.A higher score indicates worse outcomes for the patient.
Measured: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity)
Measured: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Quality of Life Indicators (e.g., CAT Score)
COPD Assessment Test (CAT):It is a short, validated, patient-reported outcome (PRO) tool specifically designed to measure the impact of pulmonary disease on a patient's health status and daily life.Score Range:Minimum score: 0 points;Maximum score: 40 points.A higher score indicates worse health status and greater pulmonary disease-related burden for the patient.
Measured: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Blood Sample Indicators (e.g., Concentration of Interleukin-8)
Assessment of Changes in Pulmonary Inflammation or Lung Injury Before and After Intervention Using Concentrations of Biomarkers Such as Interleukin-8
Measured: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2026
- Study startMar 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ILDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking Union Medical College
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hongbing Xu, Peking Union Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07344987
- Sponsor's protocol ID
- CAMS-PUMC-IRM-IAQ-ILD-2025
- Status last verified
- Jan 2026
- First submitted
- 22 Dec 2025
- Last updated
- 15 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: 1. The informed consent form signed by study participants does not include clauses authorizing the sharing of de-identified individual participant data (IPD) with external researchers. In accordance with the ethical approval requirements, no secondary use of IPD beyond the primary study objectives is permitted without explicit participant consent. 2. The sample size of this study is relatively small, and the collected IPD has high heterogeneity due to individual differences in patient clinical characteristics and intervention responsiveness. Sharing such a limited dataset may not support robust secondary research findings, and could lead to misleading interpretations of the intervention effect on pulmonary inflammation.
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Crossover Trial of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease
- ClinicalTrials.gov ID
- NCT07344987
- Acronym / sponsor ID
- CAMS-PUMC-IRM-IAQ-ILD-2025
- Conditions
- ILD
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Peking Union Medical CollegeUniversity, hospital or other
- Study start
- Mar 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 15 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Purifier (without Filter) Arm | Sham comparator | Behavioral: Purifier (without Filter) Arm |
| Air Purifier (with Filter) Arm | Experimental | Behavioral: Air Purifier (with Filter) Arm |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients diagnosed with interstitial lung disease (ILD).
- Stable disease status, defined as no hospitalization due to acute exacerbation within the past month.
Key exclusion criteria (2 listed)
- Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders.
- A history of respiratory tract infection within the past two weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Air Purifier (with Filter) ArmPlace an air purifier with high-efficiency filters in the home, and turn it on for at least 18 hours every day. | Behavioural | Air Purifier (with Filter) Arm |
| Purifier (without Filter) ArmPlace an air purifier without a filter in the home. | Behavioural | Purifier (without Filter) Arm |
Primary outcome
Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score)
Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
St. George's Respiratory Questionnaire (SGRQ):Score Range:Minimum score: 0 points;Maximum score: 100 points.A higher score indicates worse outcomes for the patient.
Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity)
Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Quality of Life Indicators (e.g., CAT Score)
Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
COPD Assessment Test (CAT):It is a short, validated, patient-reported outcome (PRO) tool specifically designed to measure the impact of pulmonary disease on a patient's health status and daily life.Score Range:Minimum score: 0 points;Maximum score: 40 points.A higher score indicates worse health status and greater pulmonary disease-related burden for the patient.
Blood Sample Indicators (e.g., Concentration of Interleukin-8)
Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Assessment of Changes in Pulmonary Inflammation or Lung Injury Before and After Intervention Using Concentrations of Biomarkers Such as Interleukin-8
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2026.
- Individual participant dataSharing planned: No. 1. The informed consent form signed by study participants does not include clauses authorizing the sharing of de-identified individual participant data (IPD) with external researchers. In accordance with the ethical approval requirements, no secondary use of IPD beyond the primary study objectives is permitted without explicit participant consent. 2. The sample size of this study is relatively small, and the collected IPD has high heterogeneity due to individual differences in patient clinical characteristics and intervention responsiveness. Sharing such a limited dataset may not support robust secondary research findings, and could lead to misleading interpretations of the intervention effect on pulmonary inflammation.
Related trials for ILD
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingObservational study
Single-Cell Sequencing Analysis of Radiation Pneumonitis Signals In Patients Treated For Cancer With Radiotherapy
Radiation Pneumonitis
RecruitingPhase 2
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
Fibrotic Interstitial Lung Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Air Purifier (with Filter) Arm and Purifier (without Filter) Arm in people with ILD, run by Peking Union Medical College.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score) (time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.